Metabolic and kidney effects of using liraglutide followed by setmelanotide in Bardet-Biedl Syndrome: a real-life case and review
Updated
Abstract
A sequential therapeutic strategy combining a glucagon-like peptide-1 (GLP-1) receptor agonist and a melanocortin-4 receptor (MC4R) agonist may offer metabolic and kidney protection in adults with Bardet-Biedl syndrome.
- Bardet-Biedl syndrome (BBS) is linked to obesity and kidney disease.
- Therapeutic options for BBS are currently limited.
- Setmelanotide is approved for obesity treatment in BBS but has limited real-world data in adults.
- The combined use of a GLP-1 receptor agonist and an MC4R agonist is suggested to have beneficial effects.
- This combination may enhance metabolic function and protect kidney health.
Simplified